Global Blood Therapeutics Stock Fundamentals
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
Global Blood Therapeutics fundamentals help investors to digest information that contributes to Global Blood's financial success or failures. It also enables traders to predict the movement of Global Stock. The fundamental analysis module provides a way to measure Global Blood's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Global Blood stock.
Global |
Global Blood Therapeutics Company Profit Margin Analysis
Global Blood's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Global Blood Profit Margin | (146.82) % |
Most of Global Blood's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Global Blood Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Global Blood Therapeutics has a Profit Margin of -146.82%. This is much higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The profit margin for all United States stocks is notably higher than that of the company.
Global Blood Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Global Blood's current stock value. Our valuation model uses many indicators to compare Global Blood value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Global Blood competition to find correlations between indicators driving Global Blood's intrinsic value. More Info.Global Blood Therapeutics is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Global Blood by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Global Blood's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Global Blood's earnings, one of the primary drivers of an investment's value.Global Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Global Blood's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Global Blood could also be used in its relative valuation, which is a method of valuing Global Blood by comparing valuation metrics of similar companies.Global Blood is currently under evaluation in profit margin category among related companies.
Global Fundamentals
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X | |||
| Price To Book | 10.19 X | |||
| Price To Sales | 20.93 X | |||
| Revenue | 210.87 M | |||
| Gross Profit | 191.43 M | |||
| EBITDA | (283.56 M) | |||
| Net Income | (309.58 M) | |||
| Cash And Equivalents | 553.42 M | |||
| Cash Per Share | 8.50 X | |||
| Total Debt | 659.05 M | |||
| Debt To Equity | 4.92 % | |||
| Current Ratio | 8.52 X | |||
| Book Value Per Share | 6.72 X | |||
| Cash Flow From Operations | (249.41 M) | |||
| Short Ratio | 5.38 X | |||
| Earnings Per Share | (4.04) X | |||
| Price To Earnings To Growth | (0.19) X | |||
| Number Of Employees | 457 | |||
| Beta | 0.86 | |||
| Market Capitalization | 4.41 B | |||
| Total Asset | 153.07 M | |||
| Retained Earnings | (758.36 M) | |||
| Working Capital | 140.1 M | |||
| Current Asset | 150.82 M | |||
| Current Liabilities | 10.72 M | |||
| Z Score | -4.3 |
About Global Blood Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Global Blood Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Global Blood using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Global Blood Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease . Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 457 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |